Kuehne+Nagel strengthens its presence in pharma and healthcare logistics in China through partnership with Jointown

Kuehne+Nagel strengthens its presence in pharma and healthcare logistics in China through partnership with Jointown

  • Extensive cooperation across warehousing, domestic distribution, international transports and logistics
  • In support of Chinese pharma customers’ access to international markets, leveraging Kuehne+Nagel’s global pharma network

(PRESS RELEASE) SHANGHAI, China, 24-Feb-2021 — /EuropaWire/ — Global transport and logistics leader Kuehne+Nagel announces a strategic partnership with China’s largest non-state-owned pharmaceutical distribution company. Partnering with Jointown further strengthens Kuehne+Nagel’s presence in China.

As one of the leading logistics providers in the world, Kuehne+Nagel has been especially focused on developing pharma & healthcare expertise for the past decade. The partnership with Jointown now affords access to their fully GxP-compliant, in-country storage and distribution network, enabling Kuehne+Nagel to comply with the highly-regulated Chinese pharma & healthcare sector.

“We are pleased to be partnering with Jointown. Our cooperation perfectly meets the demands of our global clientele by enabling seamless supply chain coverage connecting China. This will enable us to accelerate our growth in the pharma and healthcare sector in China,” says Siewloong Wong, President of Kuehne+Nagel Asia Pacific.

Zhang Qingsong, General Manager of the logistics business unit of Jointown Pharmaceutical Group, adds: “Partnering with Kuehne+Nagel will provide Jointown’s customers access to the international market through their global GxP certified air, sea and overseas contract logistics operations. We will now be able to expand our business in overseas markets at a much faster pace and benefit from the partnership in a sustainable way.”

With Covid-19 vaccines becoming widely approved for use in more countries, Jointown and Kuehne+Nagel will collaborate to manage vaccine distribution in a safe and timely manner, leveraging their respective strengths in vaccine storage and distribution both in China and other parts of the world.

Gianfranco Sgro, Member of the Management Board of Kuehne + Nagel International AG, responsible for Contract Logistics, says: “Pharma & Healthcare is one of the fastest growing sectors in Contract Logistics. Kuehne+Nagel and Jointown share a common vision of service excellence for patients and customers in China and abroad”.

The partnership with Jointown comes shortly after Kuehne+Nagel announced that it has entered into a binding agreement to acquire the Chinese company Apex International Corporation, one of Asia’s leading freight forwarders.

About Kuehne+Nagel

With over 78,000 employees at 1,400 locations in over 100 countries, the Kuehne+Nagel Group is one of the world’s leading logistics companies. Its strong market position lies in sea logistics, air logistics, road logistics and contract logistics, with a clear focus on integrated logistics solutions.

About Jointown

Jointown Pharmaceutical Group Co., Ltd. is a leading pharmaceutical company in China. Listed on the Shanghai Stock Exchange, Jointown is mainly responsible for supplying pharmaceutical drugs, traditional Chinese medicine (TCM), medical devices and consumer goods to clients including hospitals and clinics, retail pharmacies, wholesalers and government contracts. At the same time, Jointown provides e-commerce and online health management services to end users.

Jointown Logistics, an affiliate of Jointown Pharmaceutical Group is a technology-based and environmentally-friendly logistics provider dedicated to serve the health industry. It provides customers with a wide range of integrated supply chain solutions supported by an extensive distribution network and advanced information technology capabilities.

Media contacts:

Dominique Nadelhofer
Global Head of Media Communication
+41 44 786 95 26

Lily Ma
Regional Marketing Manager, China (Shanghai)

SOURCE: Kuehne+Nagel


Follow EuropaWire on Google News

Comments are closed.